Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
  • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
  • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• Proteins are known to adopt alternative, misfolded structures that can be linked to a variety of diseases. Proteins such as human Islet Amyloid Polypeptide (hlAPP, amylin) in type 2 diabetes, Ab42 in Alzheimer’s disease, and a-synuclein in Parkinson’s disease are all known to misfold and aggregate into toxic oligomers and fibers. While it is known that these misfolded proteins are toxic to cells, the exact role they play in the progression of these diseases remains a mystery.
• hlAPP human Islet Amyloid Polypeptide
• amylin amylin
• amyloid diseases represent a serious threat to human health.
• the economic and social costs associated with type 2 diabetes have been well documented over the past decade.
• the American Diabetes Association estimates that 25.8 million children and adults in the United States have diabetes, approximately 8.3% of the population with nearly 2 million new cases diagnosed each year. Because the prevalence of this disease increases with age, the number of people afflicted with type 2 diabetes will increase as our population ages. If no treatments are found to prevent or slow the progression of this disease, it is estimated that as many as 100 million Americans alone could have diabetes in the next 40 years, at a cost estimated to be more than $174 billion annually. In 2008, $116 billion was spent in the US for direct medical costs, with an additional indirect cost estimated at $58 billion for work loss, disability and premature mortality.
• IAPP amyloidogenic peptide Islet Amyloid Polypeptide
• IAPP aggregation and diabetes seems to extend to non-humans as well. Like humans, cats and primates are known to develop diabetes. Also like humans, cats and primates express IAPP variants that aggregate and form toxic amyloid. Conversely,
• IAPP variants from rat, mouse and hamster do not aggregate, nor do they form toxic amyloidogenic species. Rats, mice and hamsters do not spontaneously develop diabetes. However, when mice and rats are engineered to express human IAPP, they do develop type 2 diabetes and the symptoms associated with the disease.
• IAPP may adopt a cylindrin fold. While the structure of aggregate-forming IAPP molecules remains to be determined, it is clear that some of these aggregates are highly toxic to cells. Studies have shown that synthetic IAPP acts as a highly toxic agent in vitro when added to human islet b-cells as well as to a variety of additional mammalian cell lines. IAPP is found as extracellular deposits of amyloid in approximately 90% of patients afflicted with type 2 diabetes. IAPP has also been shown to be a toxic agent in vitro when added to mammalian cells. While it remains unclear how self-assembly of IAPP leads to the development of disease, recent studies have suggested that the formation of lower order protein aggregates (two to ten self-assembled proteins) leads to cellular toxicity and ultimately to the progression of disease.
• IAPP peptides that inhibit human IAPP aggregation and rescue mammalian cells from hlAPP toxicity. These IAPP variants are potent inhibitors of hlAPP aggregation and can be used as therapeutic agents and probes to understand the root toxicity of amyloid protein.
• the present IAPP peptides have an amino acid sequence selected from one of the following sequences:
• peptides include peptides mutated from Weddell seal IAPP (SEQ ID NOS: 15- 18), racoon IAPP (SEQ ID NOS:26-37 and SEQ ID NOS:42-46), and chicken IAPP (SEQ ID NOS:53-64 and SEQ ID NOS:65-68).
• preferred sequences include SEQ ID NOS: 16-17 (WS_RL and WS_RP); SEQ ID NO:46 (Rac_L26Y); SEQ ID NOS:31- 34 (Rl-27 to Rl-30); SEQ ID NOS:66-68 (Chvl6L, CM22L, ChY26L); and SEQ ID NOS: 59-61 (Cl -27 to Cl -29).
• IAPP peptides can be used to inhibit hlAPP aggregation in vitro or in vivo. In one embodiment, these peptides can be used in the treatment of an amyloid disease such as diabetes. When used in therapeutic applications, the IAPP peptides can be combined with one or more pharmaceutically acceptable excipients to form a pharmaceutical composition.
• IAPP peptides found naturally in cats, dogs, chickens, polar bears, raccoons, and Weddell seals can also be used in the treatment of an amyloid disease and to inhibit hlAPP aggregation. These peptides can have a sequence selected from SEQ ID NOS:2-7. The IAPP peptides of raccoon and chicken are preferred.
• the present IAPP peptides can thus be used in a method of treating a subject suffering from an amyloid disease which includes the step of administering an IAPP peptide to a subject in need thereof, where the IAPP peptide has an amino acid sequence selected from SEQ ID NOS:2-7, SEQ ID NOS: 15-18, SEQ ID NOS:26-37, SEQ ID NOS: 42-46, SEQ ID NOS:53-64, and SEQ ID NOS:65-68.
• Figure 1 is a table comparing human IAPP with IAPP of various animals. Amino acids that differ from hlAPP are indicated in bold.
• Figure 2 is a chart showing the results of a thioflavin T binding assay in which human IAPP was mixed with IAPP from other species. The average of at least three trials is shown with error bars indicating the standard deviation among trials.
• FIG. 3 shows the results of Atomic Force Microscopy (AFM) scanning of IAPP variants.
• AFM Atomic Force Microscopy
• Figure 4 is a chart showing the results of an MTT viability assay.
• the black bar at the far left shows the average viability of cells alone.
• the left-side bar above each species identifier (racoon, chicken, etc.) on the horizontal axis indicates the average cell viability upon addition of 12.8 pM hlAPP or animal IAPP variants individually.
• the right-side bar above each species identifier on the horizontal axis displays cell viability of hlAPP mixed with each animal IAPP variant (12.8 mM of a mixture of hlAPP with each indicated animal IAPP at a 1:1 ratio).
• Asterisks show a significant increase in cell viability between hlAPP alone and hlAPP mixed with raccoon or chicken IAPP variants.
• Figure 5 shows the results of AFM scanning of the indicated materials.
• Samples labeled with hlAPP contained 40 mM hlAPP.
• the sample with pramlintide and hlAPP contained a 2:1 molar mixture (80 pM Pramlintide mixed with 40 pM hlAPP).
• the samples with raccoon IAPP and Pramlintide alone contained 40 pM of the indicated peptides.
• Each sample was incubated for 40 minutes at 37°C with shaking; conditions known to promote hlAPP amyloid formation. All scans show raw data with no flattening and are 10 pm x 10 pm.
• Figure 6 is a chart showing the results of an MTT viability assay.
• the bar on the left side shows the average viability of cells alone.
• the left-side bar above each peptide identifier on the horizontal axis indicates the average cell viability upon addition of 12.8 pM hlAPP or IAPP variants individually (variants indicated on the horizontal axis).
• the right-side bar above each peptide identifier on the horizontal axis displays cell viability of hlAPP mixed with each IAPP variant (1:1 ratio of each IAPP with 12.8 pM of hlAPP).
• Figure 7 is a table listing amino acid sequences of variants of seal IAPP tested for inhibitory potential against hlAPP amyloid formation. Peptides inhibiting hlAPP amyloid formation are indicated with a bold“yes” in the“Inhibit” column, while peptides rescuing cells from hlAPP toxicity are indicated with a bold“yes” in the“Rescue” column.
• Figure 8 is a chart showing the results of a thioflavin T binding assay of hlAPP when mixed with the indicated Weddell seal IAPP peptide variants. Data show the average of a minimum of three trials with error bars showing standard deviation among trials.
• Figure 9 shows AFM images of hlAPP mixed with the indicated Weddell seal IAPP variants. All scans show raw data with no flattening and are 10 pm x 10 pm.
• Figure 10 is a chart showing the results of an MTT viability assay.
• the black bar at the far left shows the average viability of cells alone.
• the left-side bar above each peptide identifier (WS, WS-R, etc.) on the horizontal axis indicates the average cell viability upon addition of 12.8 pM hlAPP or Weddell seal IAPP variant peptide individually.
• Figure 11 is a table listing several peptides based on truncations of the sequence of full-length raccoon IAPP. Peptides inhibiting hlAPP amyloid formation are indicated with a bold“yes” in the“Inhibit” column, while peptides rescuing cells from hlAPP toxicity are indicated with a bold“yes” in the“Rescue” column.
• Figure 12 is a chart showing the results of a thio flavin T binding assay of hlAPP when mixed with the indicated raccoon IAPP variants. Human IAPP was incubated with shaking at 37°C with each indicated peptide. The four vertical bars four each peptide indicate fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes respectively, from left to right. The data show the average of a minimum of two trials with error bars showing standard deviation among trials.
• Figure 13 is a chart depicting the results shown in Figure 12 for the raccoon IAPP truncation mutants.
• the four vertical bars four each peptide indicate fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes respectively, from left to right (the 30 minute reading is not included for native racoon IAPP on the left side of the chart).
• Figure 14 is a table listing several peptides based on mutations of the sequence of raccoon IAPP. Peptides inhibiting hlAPP amyloid formation are indicated with a bold“yes” in the“Inhibit” column, while peptides rescuing cells from hlAPP toxicity are indicated with a bold“yes” in the“Rescue” column.
• Figure 15 is a chart showing the results of a thio flavin T binding assay of hlAPP when mixed with the indicated chicken and raccoon IAPP variants. Human IAPP was incubated with shaking at 37°C with each indicated peptide. The four vertical bars for each peptide indicate fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes respectively, from left to right. Data show the average of a minimum of two trials with error bars showing standard deviation among trials.
• Figure 16 is a chart showing the results of an MTT viability assay comparing variant raccoon IAPP peptides.
• the black bar at the far left shows the average viability of cells alone.
• the left-side bar above each peptide identifier on the horizontal axis indicates the average cell viability upon addition of 12.8 mM each indicated IAPP peptide individually.
• the right-side bar above each peptide identifier on the horizontal axis displays cell viability of hlAPP mixed with the indicated IAPP peptide (12.8 pM of a mixture of hlAPP with each indicated IAPP peptide at a 1:1 ratio).
• Figure 17 is a table listing several peptides based on truncations of the sequence of chicken IAPP. Peptides inhibiting hlAPP amyloid formation are indicated with a bold“yes” in the“Inhibit” column, while peptides rescuing cells from hlAPP toxicity are indicated with a bold“yes” in the“Rescue” column.
• Figure 18 is a chart showing the results of a thioflavin T binding assay of hlAPP when mixed with the indicated chicken IAPP variants. hlAPP was incubated with shaking at 37°C with each indicated peptide. The four vertical bars four each peptide indicate fluorescence after 10 minutes, 20 minutes, 25 minutes, and 30 minutes respectively, from left to right.
• FIG 19 shows the results of AFM scanning of truncated chicken and raccoon IAPP peptides.
• the Rl-23, R8-23, and R8-30 peptides did not inhibit hlAPP aggregation, while the Rl-29, Rl-27, Cl-29, and Cl-27 peptides did.
• Each sample contained 37 mM hlAPP and 75 mM of the indicated peptide. Samples were incubated at 37°C with shaking for 40 minutes. All scans show raw data with no flattening and are 10 pm x 10 pm.
• Figure 20 is a table listing several peptides based on mutations of the sequence of chicken IAPP. Peptides inhibiting hlAPP amyloid formation are indicated with a bold“yes” in the“Inhibit” column, while peptides rescuing cells from hlAPP toxicity are indicated with a bold“yes” in the“Rescue” column.
• Figure 21 is a chart showing the results of an MTT viability assay comparing variant chicken IAPP peptides.
• the black bar at the far left shows the average viability of cells alone.
• the left-side bar above each peptide identifier on the horizontal axis indicates the average cell viability upon addition of 12.8 pM hlAPP or chicken IAPP variants individually.
• the right-side bar above each peptide identifier on the horizontal axis displays cell viability of hlAPP mixed with chicken IAPP variants (12.8 pM of a mixture of hlAPP with each indicated IAPP peptide at a 1:1 ratio).
• Figure 22 shows the results of AFM scanning of raccoon and chicken IAPP variants when mixed with hlAPP.
• Each sample contained 37 pM hlAPP mixed with 37 pM of the indicated peptide.
• Samples were incubated at 37°C with shaking for 30 minutes before depositing each sample onto freshly cleaved mica.
• “About” and“approximately” refer to a quantity within 10% of the referenced quantity, unless the circumstances of such usage would indicate a different meaning. For example and not by way of limitation,“about 10” means between 9 and 11, and“about 10%” means between 9% and 11%.
• Amyloid disease refers to a medical condition which is caused by or associated with aggregates of peptides and/or proteins, in particular amylin, having a fibrillar morphology and a b-sheet secondary structure.
• Human IAPP can form oligomers or plaques, and such aggregates are associated in some cases with type II diabetes and Alzheimer’s disease.
• Cell protection refers to the ability to attenuate, mitigate, or prevent cell damage or death, in particular the toxic effects of exposure to hlAPP. Cell protection can be measured in ways known to the art, such as with cell viability and cytotoxicity assays.
• IAPP Islet Amyloid Polypeptide found in a variety of animals, in particular in mammals and birds.
• IAPP peptide refers to a peptide having one or more amino acid substitutions as compared to human IAPP (SEQ ID NO:l). IAPP peptides can be truncated as compared to hlAPP and preferably have a length which is at least 70%, 73%, 75%, 80%, 85%, 90% or more of hlAPP. Preferably, IAPP peptides have at least 80% sequence identity with hlAPP, for example 89%, 92%, 95%, or up to 97% sequence identity.
• “Inhibit,” with respect to amyloid oligomers, fibers, and aggregates, means to slow and/or prevent the formation of such oligomers, fibers, and aggregates, as compared to the formation of such materials in the absence of a material causing such inhibition.
• Amyloid formation can be measured in ways known to the art, such as with thioflavin T binding assays.
• an IAPP peptide inhibits IAPP aggregate formation by about 50% or more.
• Medical condition refers to conditions which cause disease, discomfort and/or disability in a subject.
• “Pharmaceutical effect” and“therapeutic effect” refer to an effect in restoring, correcting or modifying a physiological function of a subject, including the cure, mitigation, treatment or prevention of a medical condition in the subject.
• A“pharmaceutical” refers to an effect in restoring, correcting or modifying a physiological function of a subject, including the cure, mitigation, treatment or prevention of a medical condition in the subject.
• compositions and a“medicament” are compositions having a pharmaceutical effect.
• Treatment refers to an action which attenuates, improves, prevents, and/or resolves a medical condition. Treatment can refer to either prophylaxis or treatment following the development of a medical condition in need of treatment.
• the amino acid sequences of the naturally occurring IAPP peptides we evaluated are shown in Figure 1, with sequence differences from human IAPP shown in bold.
• the animal IAPP peptides identified as showing potential for inhibiting hlAPP aggregation are listed at the top of the figure, while those variants lacking inhibitory potential are listed at the bottom.
• IAPP peptides of cow, degu, guinea pig, horse, pig, rat, and sheep origin failed to inhibit the aggregation of human IAPP, we surprisingly found that IAPP of cat, dog, chicken, polar bear, raccoon, and seal origin were able to inhibit such aggregation when mixed with hlAPP.
• the sequences of these inhibitory IAPP peptides are shown in Table 1 below.
• Variants (mutations) of Weddell seal IAPP were prepared in order to determine their ability to inhibit aggregation of hlAPP. As shown in the table in Figure 7, some of these were found to be able to inhibit hlAPP aggregation and/or protect cells from hlAPP toxicity. These sequences are shown in Table 2 below.
• WS-LP and WS-P peptides proved to be toxic to cells, with and without addition of hlAPP.
• IAPP peptides based on the natural racoon IAPP peptide sequence were synthesized and characterized for their ability to inhibit human IAPP amyloid formation and rescue cells from hlAPP toxicity. As shown in Figures 12, 16, and 19, several IAPP peptides truncated from the C-terminal end of the raccoon IAPP peptide were found to both inhibit hlAPP aggregation and also protect cells from hlAPP toxicity.
• IAPP In view of the ability of chicken IAPP to inhibit aggregate formation by hlAPP and also rescue living cells from the toxic effects of hlAPP, a series of IAPP peptides based on the natural chicken IAPP peptide sequence were synthesized and characterized for their ability to inhibit human IAPP amyloid formation and rescue cells from hlAPP toxicity. As shown in Figures 18, 19, and 21, several IAPP peptides truncated from the C-terminal end of the chicken IAPP peptides were found to inhibit hlAPP aggregation and/or protect cells from hlAPP toxicity.
• Ch-I22L (SEQ ID NO:67) was able to inhibit hlAPP fiber formation and rescue cells from hlAPP toxicity while showing minimal inherent toxicity (see Figures 15, 21, and 22).
• any of a number of assays known to the art can be used to evaluate the ability of IAPP peptides to inhibit hlAPP aggregation and/or protect cells from hlAPP toxicity.
• Thioflavin T (ThT) binding is one such technique for identifying amyloid formation in real time.
• Human IAPP is known to bind thioflavin T during aggregation and amyloid formation, and upon binding to amyloid fibrils ThT will give a strong fluorescence signal at
• ThT fluorescence correlates linearly with amyloid concentration in a sample and therefore can be used to determine the amount of aggregation in a sample. This technique can therefore be used for identifying substances with amyloid-inhibiting potential when such substances are mixed with human IAPP under conditions known to result in the formation of aggregates by hlAPP. Determining the extent of aggregation can also be determined using other techniques, such as Atomic Force
• AFM Microscopy
• Cytoprotection can likewise be measured by a number of assays known to the art.
• MTT assay is a colorimetric assay for assessing cell metabolic activity.
• NAD(P)H-dependent cellular oxidoreductase enzymes in the cytosolic compartment of a cell reduces the tetrazolium dye MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide to an insoluble form, formazan, which has a purple color.
• MTT and other tetrazolium dyes
• depends on the cellular metabolic activity so a loss of color in the course of performing an MTT assay indicates low metabolic activity, and is thus an indicator of cell damage and death.
• IAPP peptides can be formulated as a pharmaceutical composition (medicament) for administration in ways known to the art, including intramuscular, intravenous, and subdermal administration.
• the pharmaceutical composition can be formulated as a liquid, as a powder or other solid, or as a gel.
• the IAPP peptide can be in the form of a salt, such as an acetate salt, for example.
• the pharmaceutical composition can include one or more pharmaceutically acceptable carriers and/or other pharmaceutically acceptable excipients, for example to stabilize and/or deliver the composition to a subject. Excipients for the present
• composition can include appropriate additives such as pharmaceutically effective carriers (i.e., sterile water, water, saline, and the like), buffers, neutralizing agents, stabilizers, humectants, viscosity builders, chemical stabilizers, thickeners, diluents, and/or solvents.
• pharmaceutically effective carriers i.e., sterile water, water, saline, and the like
• buffers neutralizing agents
• stabilizers i.e., sterile water, water, saline, and the like
• buffers i.e., neutralizing agents, stabilizers, humectants, viscosity builders, chemical stabilizers, thickeners, diluents, and/or solvents.
• excipients for some embodiments include, but are not limited to, alcohols and polyglycols, glycerin, waxes, water, deionized water, fatty acid esters, and the like, mixtures thereof and combinations thereof
• IAPP peptides can be used to inhibit IAPP aggregation or protect cells, as described for example in the Examples below.
• IAPP peptides are administered to cells in vitro in order to protect them from exposure to amyloid fibers such as aggregates of hlAPP, which have been found to induce cytotoxicity both when exogenously applied and when secreted from a cell.
• the present IAPP peptides can also be administered to a subject in order to reduce IAPP aggregation in vivo.
• the present IAPP peptides can be used in particular to treat human or other mammalian subjects with an amyloid disease such as diabetes.
• the present IAPP peptides which both inhibit hlAPP aggregation and protect cells from hlAPP toxicity can be administered to subjects in order to treat amyloid disease.
• Peptides derived from human IAPP which inhibit amyloid fibril formation and decrease cytotoxicity such as ANFLVH, for example, have been shown to improve fasting blood glucose levels and glucose tolerance in subjects following injection (Wijesekara et al., Diabetes, Obesity and Metabolism 17: 1003-1006, 2015).
• the IAPP peptide pramlintide has also been used to treat diabetes in humans. This peptide contains 3 amino acid substitutions found in rat IAPP. Pramlintide, however, is more amyloidogenic than the present IAPP peptides, and also does not have a cytoprotective effect.
• IAPP peptides can be administered to subjects in ways known to the art, such as by parenteral administration, for example via intramuscular, intravenous, or subdermal administration.
• an IAPP peptide composition can be administered directly to a site where aggregated IAPP is found, such as to the pancreas, specifically the pancreatic islets of Fangerhans.
• Amylin oligomers and plaques have also been identified in blood vessels, perivascular spaces, and brain tissue (parenchyma), so injection or application of an IAPP peptide composition to these organs or compartments can also be performed in order to administer the present IAPP peptides to a subject.
• the present peptides can be administered in various doses to provide effective treatments for amyloid diseases.
• Doses of from about 1 microgram (meg) to about 500 micrograms can preferably be administered to a subject, such as doses of about 2 meg, 5 meg, 7 meg, 10 meg, 15 meg,
• the present IAPP peptides can be administered for example in amounts of 0.1 meg/kg/day, 0.15 meg/kg/day, 0.2 meg/kg/day, 0.25 meg/kg/day, 0.3 meg/kg/day, 0.4 meg/kg/day, 0.5 meg/kg/day, 0.7 meg/kg/day, 0.9 meg/kg/day, 1.0 meg/kg/day, 1.2 meg/kg/day, 1.5 meg/kg/day, 1.7 meg/kg/day, 2.0 meg/kg/day, 2.2 meg/kg/day, 2.5 meg/kg/day, 3.0 meg/kg/day, 3.5 meg/kg/day, 4.0 meg/kg/day, 4.5 meg/kg/day, or 5.0 meg/kg/day, for example.
• Factors such as the aggregation-inhibiting activity of the selected peptide, half-life of the peptide, the
• physiological characteristics of the subject, the extent or nature of the subject's condition, and the method of administration will determine what constitutes an effective amount of the selected peptides, as is known to one of skill in the art. Generally, initial doses will be modified to determine the optimum dosage for treatment of the particular subject. Repeated doses of the present peptides administered over an extended period of time may be required.
• an effective amount of any embodiment of the present invention is determined using methods known to pharmacologists and clinicians having ordinary skill in the art.
• the animal models can be used to determine applicable dosages for a patient.
• a number of models for diabetes and other amyloid diseases are known.
• a transgenic mouse model of Type 2 diabetes which has been used to evaluate IAPP-derived peptides is disclosed for example by Wijesekara et al. (Diabetes, Obesity and Metabolism 17: 1003-1006, 2015).
• a very low dose of a peptide i.e. one found to be minimally toxic in animals (e.g., 1/lOxLDlO in mice), can first be administered to a patient, and if that dose is found to be safe, the patient can be treated at a higher dose.
• a peptide i.e. one found to be minimally toxic in animals (e.g., 1/lOxLDlO in mice)
• therapeutically effective amount of one of the present peptides for treating amyloid disease can then be determined by administering increasing amounts of such peptide to a patient suffering from such condition until such time as the patient's symptoms are observed or are reported by the patient to be diminished or eliminated.
• Blood levels of the present peptides can be determined using routine biological and chemical assays and these blood levels can be matched to the route of administration and half-life of a selected peptide. The blood level and route of administration can then be used to establish a therapeutically effective amount of a pharmaceutical composition comprising one of the present peptides for preventing and/or treating amyloid disease.
• raccoon and chicken IAPP were found to prevent hlAPP aggregation in the presence of human insulin, and therefore would be safe for use in conjunction with treatments for diabetes. Both raccoon and chicken IAPPs are also less aggregation-prone than Pramlintide, another diabetes treatment.
• Example 1 Thioflavin T Assay with h!APP Inhibitors from Other Species
• IAPP peptides having inhibitory potential against hlAPP aggregation were mixed with hlAPP at a 2: 1 molar ratio of animal peptide to hlAPP and incubated under conditions known to promote hlAPP aggregation and fibril formation.
• IAPP alone, or hlAPP mixed with an animal IAPP was pipetted into a glass tube and the HFIP was removed under speed-vacuum.
• the resulting peptide sample was dissolved in 20 mM Tris buffer pH 7.4.
• Aggregation was initiated by incubating samples at 37°C with shaking at 200 rpm for 40 minutes. At indicated time points, a 17 pF aliquot of each sample was mixed with 663 pF of 50.0 pM thioflavin T in 20 mM Tris buffer (pH 7.4). Thioflavin T fluorescence emission was then recorded at 488 nm using a Hitachi F-7000 fluorescence spectrophotometer.
• AFM was used to test the amyloid-inhibitory potential of each animal IAPP peptide shown in Figure 1 directly.
• Samples of hlAPP with or without animal IAPP were prepared as described in Example 1 and were then incubated with shaking at 37°C for 40 minutes. After this incubation, 17 pL of each sample was deposited onto freshly cleaved mica. Samples were incubated for 5 minutes at room temperature before washing with 200 pL sterile water. After drying, the samples were scanned using an MFP-3D atomic force microscope (Asylum Research) set on A/C mode and a 240 pm silicon cantilever (Olympus).
• Example 3 Cell viability assay with hlAPP Inhibitors from Other Species
• Hexafluoroisopropanol was removed from each individual human and animal IAPP using a centrivap concentrator (LabOnco). All IAPP peptide samples were re-suspended in RPMI-1640 with 10% FBS. To ensure even re-suspension, each resulting IAPP-containing vial was scraped with a pipette tip six times and vortexed (Vortex Genie Mixer) for 15 seconds. The whole process, from drying each IAPP peptide to adding each IAPP peptide to the cells was uniform to ensure that each sample was incubated for an equal amount of time with each IAPP peptide. IAPP peptides were added to cells and incubated for 46 hours at 37°C.
• the MTT viability assay was used to measure cell viability of RIN-m cells upon addition of hlAPP alone, the addition of each animal IAPP peptide alone, and hlAPP mixed with each animal IAPP peptide (results shown in Figure 5).
• RIN-m cells alone were used as a control and set to 100% cell viability.
• Addition of 12.8 mM human IAPP consistently resulted in a decrease in cell viability to 55+/- 5%.
• Addition of 12.8 pM raccoon, cat, seal, polar bear, and pig IAPP variants individually resulted in an average of 20-25% decrease in cell viability, while addition of chicken and rat IAPPs had an improved effect on cell viability.
• Thioflavin T binding assays were performed with the variants of raccoon IAPP shown in Figure 11. Human IAPP was mixed with each of the indicated raccoon variants and incubated at 37°C with shaking. The results are shown in Figures 12 and 13. The Rl-27, Rl- 29, and Rl-30 variants inhibited hlAPP aggregation and also rescued cells from hlAPP- induced cytotoxicity in MTT viability assays (see Figure 16).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Diabetes (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Gastroenterology & Hepatology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• General Chemical & Material Sciences (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Endocrinology (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Toxicology (AREA)
• Zoology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (2)

Family

ID=72145021

Family Applications (1)

Country Status (6)

Families Citing this family (1)

Citations (2)

Family Cites Families (16)

• 2020
  • 2020-02-24 JP JP2021549163A patent/JP7505713B2/ja active Active
  • 2020-02-24 WO PCT/US2020/019557 patent/WO2020172686A1/en not_active Ceased
  • 2020-02-24 EP EP20759401.1A patent/EP3927725A4/en active Pending
  • 2020-02-24 CN CN202410844356.7A patent/CN118955675A/zh active Pending
  • 2020-02-24 US US17/428,615 patent/US12522635B2/en active Active
  • 2020-02-24 CN CN202080015845.1A patent/CN113614101B/zh active Active
• 2021
  • 2021-08-18 IL IL285699A patent/IL285699A/en unknown
• 2024
  • 2024-06-05 JP JP2024091172A patent/JP7825238B2/ja active Active
• 2025
  • 2025-12-17 US US19/423,936 patent/US20260109744A1/en active Pending

Patent Citations (2)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events